Clinical Trial Goal
To find out:
- The highest dose of AVM0703 that’s safe to give
- If AVM0703 is safe and works well to treat blood cancer that has relapsed or is refractory in children and adults
You may be able to join this trial if you:
- Are 12 – 95 years old
- Have 1 of the following kinds of blood cancer that has relapsed or is refractory:
- Acute lymphoblastic leukemia (ALL)
- B-lymphoblastic leukemia/lymphoma
- Burkitt lymphoma
- Chronic lymphocytic leukemia (CLL)
- Diffuse large B-cell lymphoma (DLBCL)
- Mantle cell lymphoma (MCL)
- NK cell lymphoblastic leukemia/lymphoma
- Primary DLBCL of the central nervous system (CNS)
- Primary mediastinal B-cell lymphoma (PMBCL)
- Small lymphocytic lymphoma (SLL)
- T-lymphoblastic leukemia/lymphoma
- Weigh more than 88 pounds
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
AVM0703 is a drug that doctors think reduces inflammation and activates the immune system to fight cancer cells. It is sometimes called supra-pharmacologic dexamethasone sodium phosphate.
You’ll get:
You’ll get:
- AVM0703 – Given as an intravenous (IV) infusion 1 time. The infusion takes up to 2 hours. The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for 2 years.
The Food and Drug Administration (FDA) has not yet approved AVM0703.
Contacts
Theresa Deisher, PhD, 206-851-3942, tdeisher@avmbiotech.com
Sandeep Mittal, PhD, 346-401-4303, smittal@avmbiotech.com
Locations
Sponsors
collaborator: Medpace, Inc., lead: AVM Biotechnology Inc
